Action 22UA BIONTECH SE
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués BioNTech SE Xetra

Actions

22UA

US09075V1026

Marché Fermé - Xetra
Autres places de cotation
 17:43:32 17/07/2024 		Pré-ouverture 08:21:01
78,5 EUR -0,32 % Graphique intraday de BioNTech SE 79,3 +1,02 %
15/07 BIONTECH : En transition Alphavalue
12/07 Les actions européennes négociées aux États-Unis sous forme d'American Depositary Receipts grimpent dans les échanges de vendredi MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
CureVac Provides Update on Trial Dates for Patent Litigation across Multiple Geographies against Pfizer, BioNTech
AQ
Melanoma Pipeline 2024 | IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed
AQ
HAYA Therapeutics Co-Founders Win Inaugural Andreas and Thomas Struengmann Award
AQ
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union  
GL
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
GL
Africa Should Aim for New Vaccines, Therapeutics - Kagame
AQ
BioNTech : INFORMATION INCLUDED AS PART OF THIS FORM 6 K Form 6 K
PU
BioNTech : ASCO 2024
PU
BioNTech : ASCO 2024
PU
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
AQ
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
GL
Patents, Policies And Privacy: The Highs And Lows Of Technology In IP
AQ
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
AQ
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 17 May 2024)
PU
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 1 June 2022)
PU
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 22 June 2021)
PU
BioNTech : Publication of the resolutions and system for the remuneration of the members of the management Board (resolution of the AGM on 17 May 2024)
PU
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GL
MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership
PR
BioNTech : to Evaluate NanoTag’s Target Labeling System in Different Therapeutic Areas
PU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BNTX
  4. Action 22UA
  5. Actualités BioNTech SE
  6. Communiqués